The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant mouse IL4.
sELISA: Use at a concentration of 0.25 - 1 mg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant mouse IL4.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant mouse IL4 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Predicted molecular weight: 16 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes.
Genetic variations in IL4 may be a cause of susceptibility to ischemic stroke (ISCHSTR) [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.